SCM
BCAB icon

Stonepine Capital Management’s BioAtla BCAB Stock Holding History

Stonepine Capital Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5K Buy
+1,308
New +$15.3K ﹤0.01% 83

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Stonepine Capital Management's BCAB Position: Q1 2026 in Review

Stonepine Capital Management opened a new position in BioAtla (BCAB) in Q1 2026: 1,308 shares worth $10.5K. The stake represents ﹤0.01% of the portfolio and ranks #83 among its holdings.

36 funds tracked by Wall St. Rank hold BCAB as of Q1 2026.

  • Stonepine Capital Management held 1,308 shares of BioAtla worth $10.5K as of Q1 2026.
  • BioAtla was a new Stonepine Capital Management position in Q1 2026.
  • BioAtla made up ﹤0.01% of Stonepine Capital Management's portfolio in Q1 2026, its #83 holding.
  • 36 funds tracked by Wall St. Rank held BioAtla as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.